Trials / Completed
CompletedNCT02632448
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 229 (estimated)
- Sponsor
- Esperas Pharma Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Conditions
- Solid Tumors
- Colorectal Cancer
- Breast Cancer
- Ovarian Cancer
- Colon Cancer
- Rectal Cancer
- Neoplasms
- Endometrial Cancer
- Soft Tissue Sarcoma
- Triple Negative Breast Cancer
- Pancreas Cancer
- Pancreatic Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2880070 | Capsules |
| DRUG | Gemcitabine | 50 to 600 milligrams per square meter of body surface area (mg/m2) |
Timeline
- Start date
- 2016-05-16
- Primary completion
- 2025-04-14
- Completion
- 2025-04-14
- First posted
- 2015-12-16
- Last updated
- 2025-05-02
Locations
16 sites across 4 countries: United States, Canada, Croatia, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02632448. Inclusion in this directory is not an endorsement.